Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Assembly Biosciences Inc

Current price
14.52 USD -0.13 USD (-0.89%)
Last closed 14.93 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 80 322 288 USD
Yield for 12 month +1 184.96 %
21.11.2021 - 28.11.2021

Assembly Biosciences, Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study. It is also involved in novel small molecule approaches for HBV and hepatitis delta virus (HDV) comprising an orally bioavailable HBV/HDV entry inhibitor and liver-focused interferon-a receptor agonist. In addition, the company develops Herpesvirus programs, such as ABI-5366 HSV-2, a long-acting helicase inhibitor; and pan-herpes non-nucleoside polymerase inhibitors for transplant-associated infections. Further, Assembly Biosciences, Inc. has collaboration agreement with BeiGene, Ltd. to develop and commercialize the novel core inhibitor product candidates for chronic HBV infection in the People's Republic of China, Hong Kong, Taiwan, and Macau; and clinical trial collaboration agreement with Arbutus Biopharma Corporation to conduct a randomized, multi-center, and open-label clinical trials, as well as agreement with Antios Therapeutics, Inc. for triple combination therapy. The company also has license agreement with Indiana University Research and Technology Corporation for HBV research, as well as a partnership with Gilead Sciences, Inc. to develop next-generation therapeutics for serious viral diseases. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California. Address: 331 Oyster Point Boulevard, South San Francisco, CA, United States, 94080

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
MSFT MSFT Microsoft


WallStreet Target Price

36 USD

P/E ratio

Dividend Yield

Current Year

+7 163 000 USD

Last Year

Current Quarter

+7 163 000 USD

Last Quarter

Current Year

+6 713 000 USD

Last Year

-498 000 USD

Current Quarter

+7 079 000 USD

Last Quarter

-116 000 USD

Key Figures ASMB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -64 196 000 USD
Operating Margin TTM -175.22 %
PE Ratio
Return On Assets TTM -33.87 %
PEG Ratio
Return On Equity TTM -98.95 %
Wall Street Target Price 36 USD
Revenue TTM 7 163 000 USD
Book Value 7.5 USD
Revenue Per Share TTM 1.57 USD
Dividend Share
Quarterly Revenue Growth YOY -100 %
Dividend Yield
Gross Profit TTM -63 895 000 USD
Earnings Share -13.38 USD
Diluted Eps TTM -13.38 USD
Most Recent Quarter IV 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics ASMB

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ASMB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:12
Payout Ratio
Last Split Date 12.02.2024
Dividend Date

Stock Valuation ASMB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 5.8492
Price Sales TTM 11.2135
Enterprise Value EBITDA 0.7412
Price Book MRQ 1.9545

Financials ASMB

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ASMB

For 52 weeks

7.69 USD 20.04 USD
50 Day MA 12.72 USD
Shares Short Prior Month 60 233
200 Day MA 11.25 USD
Short Ratio 2.2
Shares Short 42 595
Short Percent 1.15 %

Dynamics of changes in the value of assets




414.58 USD Microsoft Corporation +0.12 (+0.03%)
Detailed analytics

ETF funds



208.70 CHF iShares MDAX UCITS ETF (DE) -11.84 (-4.92%)
Detailed analytics



2169.94 USD Gold -5.94 (-0.27%)
Detailed analytics